Stockreport

Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) [Yahoo! Finance]

Pasithea Therapeutics Corp.  (KTTA) 
PDF MIAMI, April 20, 2026 (GLOBE NEWSWIRE) Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-0 [Read more]